Cutler Group LP Amylyx Pharmaceuticals, Inc. Call Options Transaction History

Cutler Group LP

8 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q1 2024 Apr 19, 2024	SELL	$2.71 - $19.57 $2,981 - $21,527	-1,100 Reduced 31.43%	2,400 $0
Q4 2023 Jan 18, 2024	BUY	$12.07 - $18.46 $6,035 - $9,230	500 Added 16.67%	3,500 $7,000
Q3 2023 Nov 07, 2023	SELL	$18.08 - $23.45 $18,080 - $23,450	-1,000 Reduced 25.0%	3,000 $4,000
Q2 2023 Jul 18, 2023	BUY	$20.98 - $31.42 $18,882 - $28,278	900 Added 29.03%	4,000 $5,000
Q1 2023 May 01, 2023	BUY	$27.71 - $40.93 $80,359 - $118,697	2,900 Added 1450.0%	3,100 $17,000
Q4 2022 Feb 07, 2023	SELL	$29.75 - $39.26 $1.47 Million - $1.94 Million	-49,500 Reduced 99.6%	200 $1,000
Q3 2022 Oct 25, 2022	BUY	$17.15 - $30.92 $809,479 - $1.46 Million	47,200 Added 1888.0%	49,700 $27,000
Q2 2022 Aug 04, 2022	BUY	$6.85 - $19.93 $17,125 - $49,825	2,500 New	2,500 $10,000

127

44.4M

235K

530K

Ticker AMLX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 58,533,200
Market Cap $310M
Description
Amylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company's product pipeline includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment...

Get notified when there are updates to the investment portfolio of Cutler Group LP, based on Form 13F filings with the SEC.

Stay updated on Cutler Group LP with notifications on news.